Related Experiment Video
Updated: May 7, 2026
09:18
Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
Published on: September 7, 2021
Malfolded protein structure and proteostasis in lung diseases
William E Balch1, Jacob I Sznajder, Scott Budinger
11 Department of Cell Biology and Chemical Physiology, The Scripps Research Institute, La Jolla, California.
American Journal of Respiratory and Critical Care Medicine
|September 17, 2013
Summary
Disorders in protein folding and degradation are key to lung diseases. Research opportunities were identified to improve understanding and develop new treatments for lung conditions.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Proteostasis Science
Background:
- Protein folding and degradation disorders are increasingly linked to lung disease development and complications.
- Understanding these protein dynamics is crucial for advancing lung disease research.
Purpose of the Study:
- To identify research opportunities in proteostasis science relevant to lung diseases.
- To advance molecular understanding of lung pathobiology.
- To facilitate new diagnostic and therapeutic strategies for lung disease prevention and treatment.
Main Methods:
- Focused discussion at a National Heart, Lung, and Blood Institute workshop.
- Identification of knowledge gaps in proteostasis and lung disease.
- Review of recent advances in protein folding science and novel technologies.
Main Results:
- Identified key research gaps and opportunities in proteostasis and lung disease.
- Highlighted recent scientific advances in protein folding.
- Showcased novel technologies for potential therapeutic applications.
Conclusions:
- Proteostasis science offers significant opportunities for understanding and treating lung diseases.
- Further research into malformed protein structures and proteostasis is essential for clinical advancements.
- Novel technologies hold promise for improved diagnosis and therapy in pulmonary medicine.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:29Protein Folding Quality Check in the RER
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...